The investigation by Kessler Topaz Meltzer & Check, LLP into Medpace for potential securities law violations is significant. The investigation follows a reduction in revenue guidance, which could indicate financial instability or mismanagement, likely leading to negative investor sentiment and a potential short-term decline in stock price.